Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Merck (MRK) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDrug Manufacturers - GeneralMRK

Closing price · Nov 19, 2026 $132.58 -3.8% on the day · +43.6% over 12 months 52-week range $92.26 – $155.53
Get MRK alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling10last 12 months
Reported sales$79.3M0 of 36 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Feb 2, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Richard R. Deluca, Evp&Pres, Merck Animal Heallth sold 58,185 shares at $148.01 ($8.6M).

Trade date
Nov 12, 2026
Disclosed to the SEC
Nov 16, 2026
Type
Sale (code S)

Read the original SEC filing ↗All MRK insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

MRK insider transactions (Form 4)

Open-market purchases and sales. 57 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 16SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 58,185112,955 held (−34%) $148.01 $8.6M -10.4% —
Aug 13SEC Jennifer ZacharyGeneral Counsel Sell 80,31545,509 held (−64%) $133.46 $10.7M -0.7% —
Aug 13SEC Chirfi GuindoEvp, Access, Policy & Comms Sell 10,00036,613 held (−21%) $135.00 $1.4M -1.8% —
Aug 12SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 20,784134,703 held (−13%) $130.43 $2.7M +1.6% —
Aug 12SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 11,099110,767 held (−9%) $131.61 $1.5M +0.7% —
Aug 12SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 7,410127,293 held (−6%) $131.33 $973K +1.0% —
Aug 12SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 5,427121,866 held (−4%) $132.35 $718K +0.2% —
Aug 12SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 600110,167 held (−1%) $132.04 $79K +0.4% —
Aug 10SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 4,945155,787 held (−3%) $130.23 $644K +1.8% —
Aug 10SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 805160,732 held (−0%) $131.02 $105K +1.2% —
Aug 10SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 300155,487 held (−0%) $131.02 $39K +1.2% —
Aug 7SEC David Michael WilliamsEvp,Chief Info&Digital Officer Sell 34,70531,716 held (−52%) $128.77 $4.5M +3.0% —
Aug 7SEC Chirfi GuindoEvp, Access, Policy & Comms Sell 15,00046,613 held (−24%) $131.00 $2.0M +1.2% —
Aug 7SEC David Michael WilliamsEvp,Chief Info&Digital Officer Sell 13,54231,716 held (−30%) $128.77 $1.7M +3.0% —
Aug 7SEC David R. MaraldoEvp & Pres. Mmd Sell 9,70918,212 held (−35%) $128.72 $1.2M +3.0% —
Aug 7SEC David R. MaraldoEvp & Pres. Mmd Sell 6,31118,212 held (−26%) $128.72 $812K +3.0% —
Aug 7SEC David Michael WilliamsEvp,Chief Info&Digital Officer Sell 4,60031,716 held (−13%) $128.77 $592K +3.0% —
Aug 7SEC David R. MaraldoEvp & Pres. Mmd Sell 2,68618,212 held (−13%) $128.72 $346K +3.0% —
Feb 12SEC Chirfi GuindoChief Marketing Officer Sell 10,00060,615 held (−14%) $121.46 $1.2M +9.2% —
Feb 10SEC Dean Y. LiPresident Sell 10,23592,035 held (−10%) $117.52 $1.2M +12.8% —
Feb 9SEC Jennifer ZacharyGeneral Counsel Sell 56,79268,916 held (−45%) $119.15 $6.8M +11.3% —
Feb 9SEC Jennifer ZacharyGeneral Counsel Sell 38,83568,916 held (−36%) $119.15 $4.6M +11.3% —
Feb 9SEC Jennifer ZacharyGeneral Counsel Sell 25,94668,916 held (−27%) $119.15 $3.1M +11.3% —
Feb 9SEC Chirfi GuindoChief Marketing Officer Sell 10,00070,615 held (−12%) $118.41 $1.2M +12.0% —
Feb 6SEC Caroline LitchfieldCFO Sell 41,99790,192 held (−32%) $119.61 $5.0M +10.8% —
Feb 6SEC Richard R. DelucaEvp&Pres, Merck Animal Heallth Sell 37,685160,174 held (−19%) $120.92 $4.6M +9.6% —
Feb 6SEC Robert M. DavisCEO, President Sell 32,462443,602 held (−7%) $118.35 $3.8M +12.0% —
Feb 6SEC Chirfi GuindoChief Marketing Officer Sell 20,00080,615 held (−20%) $121.88 $2.4M +8.8% —
Feb 6SEC Johannes Jacobus OosthuizenPresident Sell 15,00021,197 held (−41%) $121.87 $1.8M +8.8% —
Feb 6SEC Dean Y. LiPresident Sell 15,087102,270 held (−13%) $118.77 $1.8M +11.6% —
Feb 6SEC Robert M. DavisCEO, President Sell 14,972476,064 held (−3%) $117.38 $1.8M +12.9% —
Feb 6SEC David Michael WilliamsEvp,Chief Info&Digital Officer Sell 5,00030,838 held (−14%) $121.91 $610K +8.8% —
Feb 6SEC Dalton E. Smart IIISvp Fin. - Global Controller Sell 4,00010,605 held (−27%) $119.67 $479K +10.8% —
Feb 6SEC Dalton E. Smart IIISvp Fin. - Global Controller Sell 2,4008,205 held (−23%) $119.67 $287K +10.8% —
Nov 12SEC Cristal N. DowningChief Comm. & Public Afrs Ofcr Sell 7,085 $87.00 $616K +52.4% —
Nov 4SEC David Michael WilliamsEvp,Chief Info&Digital Officer Sell 8,61424,578 held (−26%) $83.59 $720K +58.6% —
Historical context

Similar past setups: not applicable. MRK has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with MRK in the Research Lab

MRK has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

MRK closeInsider buyInsider sale
80100120140160DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-03EEarnings release filed 2026-04-30EEarnings release filed 2026-08-04EEarnings release filed 2026-10-29Sold $1,202,844 on 2026-02-10 · Dean Y. LiSold $1,214,562 on 2026-02-12 · Chirfi GuindoSold $1,350,000 on 2026-08-13 · Chirfi GuindoSold $1,691,426 on 2026-08-11 · Richard R. DelucaSold $2,437,676 on 2026-02-05 · Chirfi GuindoSold $2,710,951 on 2026-08-10 · Richard R. DelucaSold $2,753,773 on 2026-08-06 · Chirfi Guindo, Richard R. DelucaSold $6,994,541 on 2026-02-06 · David Michael Williams, Johannes Jacobus Oosthuizen, Richard R. DelucaSold $8,611,875 on 2026-11-12 · Richard R. DelucaSold $9,212,942 on 2026-08-05 · David Michael Williams, David R. MaraldoSold $12,258,487 on 2026-08-12 · Jennifer Zachary, Richard R. DelucaSold $13,180,383 on 2026-02-04 · Caroline Litchfield, Dalton E. Smart III, Dean Y. Li, Robert M. DavisSold $15,669,791 on 2026-02-09 · Chirfi Guindo, Jennifer Zachary
Bought, 12 months$0
Sold, 12 months$79.3M
Insiders buying0
Insiders selling10

Merck insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 10 sold $79.3M of MRK stock on the open market; P/E 110.7 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

MRK insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $1.3M sold (2 trades)Q4 2025Q1 2026: $40.7M sold (16 trades)Q1 2026Q2 2026Q3 2026: $30.0M sold (17 trades)Q3 2026Q4 2026: $8.6M sold (1 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$8.6M1
Q3 2026—0$30.0M17
Q2 2026—0—0
Q1 2026—0$40.7M16
Q4 2025—0$1.3M2

Valuation, profit and volume

P/E (trailing)110.7Sector median 25.0
Market value$344.27BDrug Manufacturers - General
Profit margin4.8%Revenue growth +5.1%
Volume vs. 50-day0.8×Last 5 sessions

Source: Yahoo Finance, as of Oct 5, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Merck & Co. insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $79.3M. 0 of 36 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

MRK earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 29, 2026 -0.7% None +6.1%S&P -2.1% pending
Aug 4, 2026 +0.2% None +0.4%S&P +1.6% +17.1%
Apr 30, 2026 -7.5% None +1.1%S&P +1.3% +5.8%
Feb 3, 2026 +4.2% None +4.4%S&P -1.3% -2.1%
Oct 30, 2025 +2.2% None -0.7%S&P -0.8% +21.9%
Jul 29, 2025 +0.8% None -2.7%S&P -0.4% +2.9%
Apr 24, 2025 -0.3% None +5.1%S&P +2.8% -6.2%
Feb 4, 2025 +1.9% None -10.1%S&P +1.1% +5.6%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

MRK short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 51% of volume sold short2026-08-27: 49% of volume sold short2026-08-28: 42% of volume sold short2026-08-31: 50% of volume sold short2026-09-01: 57% of volume sold short2026-09-02: 57% of volume sold short2026-09-03: 44% of volume sold short2026-09-04: 48% of volume sold short2026-09-08: 64% of volume sold short2026-09-09: 57% of volume sold short2026-09-10: 48% of volume sold short2026-09-11: 45% of volume sold short2026-09-14: 47% of volume sold short2026-09-15: 56% of volume sold short2026-09-16: 47% of volume sold short2026-09-17: 46% of volume sold short2026-09-18: 51% of volume sold short2026-09-21: 32% of volume sold short2026-09-22: 34% of volume sold short2026-09-23: 16% of volume sold short2026-09-24: 15% of volume sold short2026-09-25: 36% of volume sold short2026-09-28: 38% of volume sold short2026-09-29: 25% of volume sold short2026-09-30: 20% of volume sold short2026-10-01: 27% of volume sold short2026-10-02: 33% of volume sold short2026-10-05: 24% of volume sold short2026-10-06: 40% of volume sold short2026-10-07: 40% of volume sold short2026-10-08: 38% of volume sold short2026-10-09: 51% of volume sold short2026-10-12: 41% of volume sold short2026-10-13: 27% of volume sold short2026-10-14: 51% of volume sold short2026-10-15: 41% of volume sold short2026-10-16: 41% of volume sold short2026-10-19: 24% of volume sold short2026-10-20: 35% of volume sold short2026-10-21: 44% of volume sold short2026-10-22: 49% of volume sold short2026-10-23: 42% of volume sold short2026-10-26: 26% of volume sold short2026-10-27: 37% of volume sold short2026-10-28: 17% of volume sold short2026-10-29: 25% of volume sold short2026-10-30: 31% of volume sold short2026-11-02: 47% of volume sold short2026-11-03: 35% of volume sold short2026-11-04: 34% of volume sold short2026-11-05: 43% of volume sold short2026-11-06: 42% of volume sold short2026-11-09: 39% of volume sold short2026-11-10: 50% of volume sold short2026-11-11: 40% of volume sold short2026-11-12: 53% of volume sold short2026-11-13: 49% of volume sold short2026-11-16: 32% of volume sold short2026-11-17: 45% of volume sold short2026-11-18: 43% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 43%20-day average: 38%Prior 2 months: 40%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded MRK

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Sold $15,001 - $50,000 Mar 27, 2026Jul 21, 2026 +12.3%

Insiders at Merck & Co.

InsiderBoughtSoldLast filingPast buys beat S&PScore
Jennifer ZacharyGeneral Counsel — $25.2M Aug 13, 2026 — —
Richard R. DelucaEvp&Pres, Merck Animal Heallth — $19.9M Nov 16, 2026 — —
Chirfi GuindoEvp, Access, Policy & Comms — $8.2M Aug 13, 2026 — —
David Michael WilliamsEvp,Chief Info&Digital Officer — $8.1M Aug 7, 2026 — —
Robert M. DavisCEO, President — $5.6M May 1, 2026 — —
Caroline LitchfieldCFO — $5.0M May 1, 2026 — —
Dean Y. LiPresident — $3.0M May 1, 2026 — —
David R. MaraldoEvp & Pres. Mmd — $2.4M Aug 7, 2026 — —
Johannes Jacobus OosthuizenEvp, Oncology & Int?L — $1.8M May 1, 2026 — —
Dalton E. Smart IIISvp Fin. - Global Controller — $766K May 5, 2026 — —
Cristal N. DowningChief Comm. & Public Afrs Ofcr — $616K Nov 12, 2025 — —
Betty D. LarsonEvp, Chief Hr Officer — — May 1, 2026 — —
Sanat ChattopadhyayExe V-P & Pres. Mmd — — May 1, 2026 — —
Joseph RomanelliPresident — — Jan 28, 2026 — —

Board links: companies that share insiders with MRK

Directors and executives who filed Form 4s for MRK and another company in the last 12 months.

See the map →

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

MRK stock: common questions

Are Merck & Co. insiders buying MRK stock?

No. No Merck & Co. insider reported an open-market purchase of MRK in the past 12 months.

Are Merck & Co. insiders selling MRK stock?

10 insiders reported sales worth $79.3M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is MRK's P/E ratio?

MRK trades at about 110.7 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is MRK's 52-week range?

Over the past year MRK has traded between $92.26 and $155.53. It last closed at $132.58 on Nov 19, 2026.